Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BMS-986278 in idiopathic pulmonary fibrosis
CTR20234124Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of admilparant in idiopathic pulmonary fibrosis (IPF), sponsored by Bristol Myers Squibb. Started Mar 2024; status: active.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20234124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234124.